{"id":"angiotensin-ii-infusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Arrhythmias"},{"rate":null,"effect":"Thrombosis"},{"rate":null,"effect":"Ischemia"}]},"_chembl":{"chemblId":"CHEMBL4303676","moleculeType":"Small molecule","molecularWeight":"1046.20"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Angiotensin II is a potent endogenous vasoconstrictor hormone that activates angiotensin II type 1 (AT1) and type 2 (AT2) receptors. When administered as an infusion, it causes rapid vasoconstriction of arterioles and veins, increases systemic vascular resistance, and elevates blood pressure. This mechanism is used therapeutically in critically ill patients with severe hypotension refractory to other vasopressors.","oneSentence":"Angiotensin II directly binds to angiotensin II receptors (AT1 and AT2) on vascular smooth muscle and other tissues to increase vasoconstriction and blood pressure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:42:23.776Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypotension in critically ill patients refractory to conventional vasopressors"}]},"trialDetails":[{"nctId":"NCT04901169","phase":"PHASE2, PHASE3","title":"Angiotensin II in Liver Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2022-06-28","conditions":"Liver Transplant; Complications, Vasoplegia","enrollment":50},{"nctId":"NCT06746753","phase":"PHASE4","title":"Dysfunctional Renin-Angiotensin System in Septic Shock","status":"NOT_YET_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2026-03","conditions":"Septic Shock","enrollment":78},{"nctId":"NCT06693726","phase":"PHASE4","title":"Early Angiotensin II in the Emergency Department","status":"RECRUITING","sponsor":"Brett A Faine","startDate":"2025-04-01","conditions":"Septic Shock","enrollment":20},{"nctId":"NCT07312292","phase":"PHASE2","title":"Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)","status":"NOT_YET_RECRUITING","sponsor":"Niek Wijnen","startDate":"2026-01-01","conditions":"Liver Cancer (Locally Advanced or Metastatic), Liver Cancer Adult","enrollment":15},{"nctId":"NCT02966665","phase":"PHASE1","title":": Vascular Function in Health and Disease","status":"RECRUITING","sponsor":"Russell Richardson","startDate":"2008-09","conditions":"Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure","enrollment":420},{"nctId":"NCT06482853","phase":"EARLY_PHASE1","title":"Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension","status":"RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2025-01-23","conditions":"Obesity, Hypertension","enrollment":52},{"nctId":"NCT05301192","phase":"EARLY_PHASE1","title":"Angiotensin-(1-7) Cardiovascular Effects in Aging","status":"RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2022-12-09","conditions":"Aging","enrollment":26},{"nctId":"NCT03777215","phase":"EARLY_PHASE1","title":"Angiotensin-(1-7) and Energy Expenditure in Human Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amy Arnold","startDate":"2019-09-26","conditions":"Obesity","enrollment":30},{"nctId":"NCT00962949","phase":"PHASE1","title":"The Renin-Aldosterone Axis in Postural Tachycardia Syndrome","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2009-04","conditions":"Postural Orthostatic Tachycardia Syndrome (POTS)","enrollment":28},{"nctId":"NCT04592744","phase":"PHASE4","title":"Angiotensin 2 for AKI After OLT","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, Los Angeles","startDate":"2022-04-08","conditions":"Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury","enrollment":30},{"nctId":"NCT03733145","phase":"PHASE4","title":"Angiotensin II in General Anesthesia","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2019-10-03","conditions":"Hypertension","enrollment":32},{"nctId":"NCT06615102","phase":"PHASE3","title":"Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II","status":"RECRUITING","sponsor":"Universität Münster","startDate":"2025-03-31","conditions":"Cardiac Surgery, Vasoplegia","enrollment":1022},{"nctId":"NCT02646475","phase":"PHASE1","title":"Metabolic Effects of Angiotensin-(1-7)","status":"RECRUITING","sponsor":"Vanderbilt University","startDate":"2016-02","conditions":"Obesity, Insulin Resistance, Hypertension","enrollment":26},{"nctId":"NCT06234592","phase":"NA","title":"The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock","status":"RECRUITING","sponsor":"King's College Hospital NHS Trust","startDate":"2024-01-05","conditions":"Septic Shock, Acute Kidney Injury","enrollment":45},{"nctId":"NCT04053764","phase":"PHASE2","title":"Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-12-10","conditions":"Sickle Cell Disease (SCD)","enrollment":58},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT03604289","phase":"EARLY_PHASE1","title":"Angiotensin 1-7 in Obesity Hypertension","status":"TERMINATED","sponsor":"Amy Arnold","startDate":"2019-04-01","conditions":"Obesity, Hypertension","enrollment":8},{"nctId":"NCT06122987","phase":"PHASE4","title":"Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock","status":"RECRUITING","sponsor":"Kingman Regional Medical Center","startDate":"2023-12-04","conditions":"Septic Shock, Shock, Sepsis","enrollment":50},{"nctId":"NCT03240068","phase":"EARLY_PHASE1","title":"Angiotensin-(1-7) in Peripheral Arterial Disease","status":"TERMINATED","sponsor":"Milton S. Hershey Medical Center","startDate":"2017-09-01","conditions":"Peripheral Arterial Disease","enrollment":6},{"nctId":"NCT04048707","phase":"PHASE2","title":"Angiotensin 2 for Hepatorenal Syndrome","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2021-07-01","conditions":"Hepatorenal Syndrome, Cirrhosis, Kidney Failure, Acute","enrollment":""},{"nctId":"NCT04904562","phase":"PHASE4","title":"Angiotensin II for Distributive Shock","status":"UNKNOWN","sponsor":"Northwestern University","startDate":"2022-06-01","conditions":"Distributive Shock","enrollment":40},{"nctId":"NCT05824390","phase":"PHASE4","title":"A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy","status":"UNKNOWN","sponsor":"XIEJINGYUAN","startDate":"2020-06-20","conditions":"IgA Nephropathy","enrollment":116},{"nctId":"NCT05199493","phase":"PHASE3","title":"Reducing Acute Kidney Injury Occurence by Administering Angiotensin II","status":"COMPLETED","sponsor":"Universität Münster","startDate":"2021-12-27","conditions":"Cardiac Surgery, Vasoplegia, Hyperreninemia","enrollment":64},{"nctId":"NCT03217825","phase":"PHASE2","title":"Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan","status":"COMPLETED","sponsor":"Windtree Therapeutics","startDate":"2015-12","conditions":"Hypertension","enrollment":240},{"nctId":"NCT01508468","phase":"PHASE3","title":"Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-01-17","conditions":"Idiopathic Membranous Nephropathy","enrollment":80},{"nctId":"NCT01210430","phase":"EARLY_PHASE1","title":"Local Vasoconstriction in Postural Tachycardia Syndrome","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2010-07","conditions":"Postural Tachycardia Syndrome","enrollment":74},{"nctId":"NCT04647552","phase":"","title":"Effects of Hydrocortison Treatment on Angiotensin II and Angiotensin II Receptors in Patients With Septic Shock","status":"COMPLETED","sponsor":"Inonu University","startDate":"2020-11-01","conditions":"Shock, Septic","enrollment":40},{"nctId":"NCT02591173","phase":"EARLY_PHASE1","title":"Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2016-02","conditions":"Autonomic Nervous System Disorders, Pure Autonomic Failure, Shy-Drager Syndrome","enrollment":7},{"nctId":"NCT01121120","phase":"PHASE2","title":"Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients","status":"TERMINATED","sponsor":"Tarix Pharmaceuticals","startDate":"2010-06","conditions":"Lymphoma, Non-Hodgkin, Hodgkin Disease, Multiple Myeloma","enrollment":75},{"nctId":"NCT01502787","phase":"PHASE4","title":"Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2009-04","conditions":"Hypertension","enrollment":46},{"nctId":"NCT03302650","phase":"PHASE3","title":"Angiotensin II for Septic Shock Treatment","status":"SUSPENDED","sponsor":"Cairo University","startDate":"2019-04-01","conditions":"Septic Shock","enrollment":20},{"nctId":"NCT03623529","phase":"PHASE2","title":"A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock","status":"UNKNOWN","sponsor":"La Jolla Pharmaceutical Company","startDate":"2018-08","conditions":"Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock","enrollment":100},{"nctId":"NCT03431077","phase":"PHASE2","title":"A Study of LJPC-501 in Pediatric Patients With Hypotension","status":"COMPLETED","sponsor":"La Jolla Pharmaceutical Company","startDate":"2018-02-11","conditions":"Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock","enrollment":2},{"nctId":"NCT02344602","phase":"PHASE4","title":"The Effect of Uric Acid Lowering in Type 1 Diabetes","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2012-12-18","conditions":"Type 1 Diabetes Mellitus","enrollment":73},{"nctId":"NCT01407237","phase":"","title":"Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2012-01","conditions":"HIV-infection","enrollment":30},{"nctId":"NCT01906307","phase":"PHASE1","title":"A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome","status":"TERMINATED","sponsor":"La Jolla Pharmaceutical Company","startDate":"2014-03","conditions":"Hepatorenal Syndrome Type I and Type II","enrollment":6},{"nctId":"NCT00711789","phase":"PHASE2","title":"Angiotensin in Septic Kidney Injury Trial","status":"UNKNOWN","sponsor":"Austin Health","startDate":"2010-02","conditions":"Acute Renal Failure, Sepsis, Septic Shock","enrollment":12},{"nctId":"NCT01049646","phase":"NA","title":"Interaction of Apelin and Angiotensin in the Systemic Circulation","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2010-01","conditions":"Renin Angiotensin System","enrollment":12},{"nctId":"NCT00901719","phase":"NA","title":"Investigating Systemic and Local Vascular Responses to Apelin in the Context of Renin-angiotensin Upregulation","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2010-04","conditions":"Heart Disease, Heart Failure, Vasodilatation","enrollment":12},{"nctId":"NCT00901745","phase":"NA","title":"Interaction of Apelin and Angiotensin in the Human Forearm Circulation","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2009-05","conditions":"Heart Disease, Vasodilation","enrollment":12},{"nctId":"NCT00901888","phase":"NA","title":"Interaction of Apelin and Angiotensin in the Human Forearm Circulation","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2009-04","conditions":"Heart Disease, Vasodilation","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1127,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Angiotensin II Infusion","genericName":"Angiotensin II Infusion","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Angiotensin II directly binds to angiotensin II receptors (AT1 and AT2) on vascular smooth muscle and other tissues to increase vasoconstriction and blood pressure. Used for Hypotension in critically ill patients refractory to conventional vasopressors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}